Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

Table 2 SARS-CoV-2 IgM and/or IgG positivity percentages of patients (divided into oncology units) and healthcare providers

Oncology unit category	Treatment	Number of patients	IgM and IgG negative		IgM and/or IgG positive		p-value
Oncology unit category	Treatment	Number of patients	Number of patients	Percentage of patients	Number of patients	Percentage of patients	p-value
Melanoma	ICIs	287	278	96.9	9	3.1	–
Breast	CHTs	183	165	90.2	18	9.8	–
Thoraco-pulmonary	CHTs	16	15	93.8	1	6.3
Uro-gynaecological	CHTs	118	114	96.6	4	3.4
Head-neck	CHTs	16	16	100.0	0	0.0
Sarcoma	CHTs	30	27	90.0	3	10.0
Gastro-intestinal	CHTs	235	222	94.47	13	5.5
Total CHTs “non melanoma” patients	CHTs	598	559	93.5	39	6.5	0.04*

Category	Number of cases	IgM and IgG negative		IgM and/or IgG positive		p-value
Category	Number of cases	Number of subjects	Percentage of subjects	Number of subjects	Percentage of subjects	p-value
Healthcare providers	1050	1002	95.4	48	4.6	0.29**

ICIs Immune Checkpoint Inhibitors Treatment, CHTs chemotherapy treatments
^*Comparison ICIs vs. CHTs patients’ SARS-CoV-2 IgM and/or IgG positivity percentages (statistically significant) (Pearson’s χ² test was used to identify differences in the proportions of individuals between two categories)
^**Comparison ICIs patients’ vs. Healthcare Providers’ SARS-CoV-2 IgM and/or IgG positivity percentages (not statistically significant) (Pearson’s χ² test was used to identify differences in the proportions of individuals between two categories)

ISSN: 1479-5876